Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities

[1]  John A. Tallarico,et al.  Rational Chemical Design of Molecular Glue Degraders , 2022, bioRxiv.

[2]  S. Cowley,et al.  A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras , 2022, RSC medicinal chemistry.

[3]  S. Cowley,et al.  Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs) , 2022, Biochemistry.

[4]  J. Mackay,et al.  A NuRD for all seasons. , 2022, Trends in biochemical sciences.

[5]  A. Gopalsamy.  Selectivity through Targeted Protein Degradation (TPD). , 2022, Journal of medicinal chemistry.

[6]  S. Cowley,et al.  Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells , 2022, Journal of medicinal chemistry.

[7]  X. Chen,et al.  Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers , 2022, Nature Communications.

[8]  John G Doench,et al.  Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers , 2021, Nature Genetics.

[9]  Michael A. Erb,et al.  Enabling cancer target validation with genetically encoded systems for ligand-induced protein degradation , 2021, Current Research in Chemical Biology.

[10]  A. Berger,et al.  Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome , 2021, Cell reports.

[11]  A. Razov,et al.  Chemo-proteomics exploration of HDAC degradability by small molecule degraders. , 2021, Cell chemical biology.

[12]  Joshua M. Dempster,et al.  Selective modulation of a pan-essential protein as a therapeutic strategy in cancer. , 2021, Cancer discovery.

[13]  Natalie S. Scholes,et al.  Identification and selectivity profiling of small-molecule degraders via multi-omics approaches. , 2021, Cell chemical biology.

[14]  Joshua M. Dempster,et al.  A First-Generation Pediatric Cancer Dependency Map , 2021, Nature Genetics.

[15]  G. Winter,et al.  Fast-acting chemical tools to delineate causality in transcriptional control. , 2021, Molecular cell.

[16]  André F. Rendeiro,et al.  Acute BAF perturbation causes immediate changes in chromatin accessibility , 2021, Nature Genetics.

[17]  W. Sellers,et al.  Targeting pan-essential genes in cancer: challenges and opportunities. , 2020, Cancer cell.

[18]  P. Gaulard,et al.  Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma , 2020 .

[19]  J. Khan,et al.  NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency , 2020, eLife.

[20]  S. Schreiber,et al.  An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells , 2020, Cell.

[21]  A. Look,et al.  ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression , 2020, Science Advances.

[22]  S. Cowley,et al.  PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes. , 2020, Chemical communications.

[23]  J. Mackay,et al.  The Nucleosome Remodeling and Deacetylase Complex Has an Asymmetric, Dynamic, and Modular Architecture , 2020, bioRxiv.

[24]  P. Northcott,et al.  Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma , 2020, Cell reports.

[25]  David M. Wilson,et al.  EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. , 2019, Cell chemical biology.

[26]  A. Ashworth,et al.  Synthetic lethality as an engine for cancer drug target discovery , 2019, Nature Reviews Drug Discovery.

[27]  J. Khan,et al.  Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma , 2019, Nature Genetics.

[28]  Teng Teng,et al.  Optimization of AsCas12a for combinatorial genetic screens in human cells , 2019, bioRxiv.

[29]  J. Khan,et al.  Chemical genomics reveals histone deacetylases are required for core regulatory transcription , 2019, Nature Communications.

[30]  Matthew C. Canver,et al.  Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis , 2019, Nature Genetics.

[31]  Arndt von Haeseler,et al.  Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets , 2019, BMC Bioinformatics.

[32]  M. Koegl,et al.  BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design , 2019 .

[33]  G. Parmigiani,et al.  Deciphering the chronology of copy number alterations in Multiple Myeloma , 2019, Blood Cancer Journal.

[34]  Dorte B. Bekker-Jensen,et al.  Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma , 2018, Science Signaling.

[35]  C. Lareau,et al.  A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation , 2018, Nature Cell Biology.

[36]  Paul Bertone,et al.  The Nucleosome Remodeling and Deacetylation Complex Modulates Chromatin Structure at Sites of Active Transcription to Fine-Tune Gene Expression , 2018, Molecular cell.

[37]  R. Young,et al.  Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry , 2018, Nature Genetics.

[38]  Aviad Tsherniak,et al.  Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. , 2018, Cell systems.

[39]  James E. Bradner,et al.  The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.

[40]  Donald R. Polaski,et al.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.

[41]  T. Golub,et al.  CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2 , 2017, The Journal of clinical investigation.

[42]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[43]  Johannes Zuber,et al.  Thiol-linked alkylation of RNA to assess expression dynamics , 2017, Nature Methods.

[44]  S. Henikoff,et al.  Targeted in situ genome-wide profiling with high efficiency for low cell numbers , 2018, Nature Protocols.

[45]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[46]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[47]  Howard Y. Chang,et al.  Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. , 2017, Cancer cell.

[48]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[49]  Catarina P. Santos,et al.  Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts , 2017, bioRxiv.

[50]  S. Armstrong,et al.  Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. , 2017, Angewandte Chemie.

[51]  J. Schwabe,et al.  Targeting Class I Histone Deacetylases in a "Complex" Environment. , 2017, Trends in pharmacological sciences.

[52]  James E. Bradner,et al.  A chemical probe toolbox for dissecting the cancer epigenome , 2017, Nature Reviews Cancer.

[53]  Neville E. Sanjana,et al.  Transcription control by the ENL YEATS domain in acute leukemia , 2016, Nature.

[54]  E. Seto,et al.  HDACs and HDAC Inhibitors in Cancer Development and Therapy. , 2016, Cold Spring Harbor perspectives in medicine.

[55]  Kyle L. Morris,et al.  The structure of the core NuRD repression complex provides insights into its interaction with chromatin , 2016, eLife.

[56]  J. Shearstone,et al.  Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2 , 2016, PloS one.

[57]  Mariko Sasaki,et al.  Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. , 2016, Cancer discovery.

[58]  Tetsushi Sakuma,et al.  MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems , 2015, Nature Protocols.

[59]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[60]  J. Zuber,et al.  Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. , 2015, Blood.

[61]  F. Speleman,et al.  Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma , 2015, Cancer Cell International.

[62]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[63]  Sebastian A. Wagner,et al.  Acetylation site specificities of lysine deacetylase inhibitors in human cells , 2015, Nature Biotechnology.

[64]  Tina N. Davis,et al.  Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL , 2015, Clinical Cancer Research.

[65]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[66]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[67]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2014, Nature Reviews Drug Discovery.

[68]  O. Dovey,et al.  Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells , 2014, Proceedings of the National Academy of Sciences.

[69]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[70]  C. Roberts,et al.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.

[71]  W. Hahn,et al.  Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation , 2014, Molecular and Cellular Biology.

[72]  J. Yokota,et al.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.

[73]  O. Dovey,et al.  Histone deacetylase (HDAC) 1 and 2 are essential for normal T cell development and genomic stability in mice , 2013, Clinical Epigenetics.

[74]  S. Cowley,et al.  The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. , 2013, Biochemical Society transactions.

[75]  Giovanni Roti,et al.  Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. , 2013, Chemistry & biology.

[76]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[77]  L. Wessels,et al.  Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. , 2013, Blood.

[78]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[79]  P. Wade,et al.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex , 2011, Nature Reviews Cancer.

[80]  J. Epstein,et al.  Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. , 2010, Developmental cell.

[81]  R. DePinho,et al.  Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis , 2010, The EMBO journal.

[82]  O. Dovey,et al.  Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation , 2010, Proceedings of the National Academy of Sciences.

[83]  H. Kohler,et al.  Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. , 2010, Genes & development.

[84]  V. P. Collins,et al.  Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia , 2008, Leukemia & lymphoma.

[85]  R. Starke,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma—A Critical Review , 2008, Clinical medicine. Oncology.

[86]  S. Denslow,et al.  The human Mi-2/NuRD complex and gene regulation , 2007, Oncogene.

[87]  F. Bertoni,et al.  Chromosome band 6q deletion pattern in malignant lymphomas. , 2006, Cancer genetics and cytogenetics.

[88]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[90]  Gudrun Schleiermacher,et al.  Gene expression profiling of 1p35–36 genes in neuroblastoma , 2004, Oncogene.

[91]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[92]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[93]  G. Gahrton,et al.  6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. , 1998, Blood.

[94]  S. Schreiber,et al.  A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.

[95]  A. Look,et al.  Significance of chromosome 1p loss of heterozygosity in neuroblastoma. , 1995, Cancer research.

[96]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N–myc amplification , 1993, Nature Genetics.

[97]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.